Latest Breaking News On - Staffan stro - Page 2 : vimarsana.com

Annual General Meeting of Infant Bacterial Therapeutics

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2023, among other things, the following was resolved: to adopt the.

Staffan stroMargareta hagmanAnthon jahreskogMaria ekdahlArticles of associationAudit committeeAnnual general meetingInfant bacterial therapeuticsPeter rothschildNominating committeeNasdaq stockholm

Infant Bacterial Therapeutics AB (publ) Interim report January 1- December 31, 2022

Infant Bacterial Therapeutics AB (publ) Interim report January 1- December 31, 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomMaria ekdahlStaffan stroAustralian patent officeData monitoring committeeWall streetMarket accessBritish journalConnection studyNasdaq stockholm

Infant Bacterial Therapeutics AB (publ) Interim report

Message from the CEO The speed of recruitment of preterm infants into our large phase 3 study significantly increased in the final three months of.

United kingdomMaria ekdahlStaffan stroAustralian patent officeData monitoring committeeMarket accessBritish journalConnection studyNasdaq stockholmStockholm stock exchange ibt bInfant bacterial therapeutics abInfant bacterial therapeuticsFinancial reportPremature infantsOrphan drug

Investegate |Infant Bacterial Therapeutics Announcements | Infant Bacterial Therapeutics: Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2021

Investegate announcements from Infant Bacterial Therapeutics, Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2021

United statesHong kongNew jerseyRobert molanderStaffan stroMichael owensJosef neuAustralian patent officeUniversity of floridaData monitoring committeeMexican patent officeData monitor committeeChinese patent officeClinical research organizationJapan patent officeInfant bacterial therapeutics

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - March 31, 2021 Message from the CEO IBT is conducting a phase III-study ( The Connection Study ) which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414 containing Lactobacillus reuteri as active substance. The active substance is a human bacterial strain found naturally in breast milk. The objective of the study is to show that the active substance can prevent necrotizing enterocolitis (NEC) and improve sustained feeding tolerance. The medical need of a well-functioning digestion system is very high in premature infants and it is our expectation that IBT s pharmaceutical candidate IBP-9414 may improve gut motility in nutritional uptake, and simultaneously also reduce the risk for several complications such as NEC.

United statesStaffan stroDaniel mackeyChinese patent officeJapan patent officeData monitoring committeeOrphan drugConnection studyNasdaq stockholmஒன்றுபட்டது மாநிலங்களில்பணியாளர் ஸ்ட்ரோடேனியல் மேக்கிசீன காப்புரிமை அலுவலகம்ஜப்பான் காப்புரிமை அலுவலகம்தகவல்கள் கண்காணிப்பு குழுஆர்ஃபந் மருந்து